Is Dianthus Therapeutics, Inc. (DNTH) a Buy, Sell, or Hold?
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$101.28 USD
$2.64 (2.68%)
- Volume
- 1.17M
- Average Volume
- 937.49K
- Market Capitalization
- $4.23B
- P/E Ratio
- -920.73
- Dividend Yield
- 0.00%
- Price Target
- $120.00
- Year High
- $102.37
- Year Low
- $18.08
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $29.25
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Marino Garcia |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | DNTH |
| CUSIP | 252828108 |
| CIK | 0001690585 |
| Web | https://dianthustx.com |
| Phone | 929-999-4055 |
| Currency | USD |
| Employees | 92 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 29.25 |
| Quick Ratio | 29.25 |
| Cash Ratio | 16.40 |
Sales & Book Value
| Annual Sales | $2.04M |
| Price / Sales | 3165.00 |
| Cash Flow | -2.72 |
| Price / Cash Flow | -32.41 |
| Price / Book | 4.05 |
Price Target and Rating
| Average Stock Price Forecast | $120.00 |
| High Stock Price Forecast | $145.00 |
| Low Stock Price Forecast | $55.00 |
| Forecast Upside/Downside | -15.60% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 10 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.2 |
| Trailing P/E Ratio | -920.73 |
| PEG Ratio | -13595.04 |
| P/E Growth | -13595.04 |
| Net Income | $-162.34M |
| Net Margin | -847.53% |
| Pretax Margin | -847.53% |
| Return on Equity | -1.78% |
| Return on Assets | -0.91% |
Financials Score
| AltmanZ Score | 56.26 |
| Piotroski Score | 1.00 |
| Working Capital | 1.08B |
| Total Assets | 1.25B |
| Ebit | -11.32M |
| Market Cap | 4.23B |
| Total Liabilities | 45.57M |
Poll Results
About Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. ...
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
2026-07-02 16:01:00
NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on July 1, 2026, to five newly-hired, non-executive employees.
2026-06-29 07:00:00
EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?
2026-06-17 11:30:54
Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.
Why Is Dianthus Therapeutics Stock Trading Higher On Friday?
2026-06-12 13:20:36
Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported stronger-than-expected midstage results from its CAPTIVATE Phase 3 trial of claseprubart (DNTH103) in chronic inflammatory demyelinating polyneuropathy (CIDP).
2026-06-09 17:12:12
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-02 16:01:00
NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on June 1, 2026, to three newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
2026-05-30 10:06:23
Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win
Dianthus Therapeutics to Participate in Two Investor Conferences
2026-05-26 16:01:00
NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in two investor conferences in June 2026.
Frequently Asked Questions
-
What is the current Dianthus Therapeutics, Inc. (DNTH) stock price?
-
Dianthus Therapeutics, Inc.(NASDAQ:DNTH) stock price is $101.28 in the last trading session. During the trading session, DNTH stock reached the peak price of $102.37 while $18.08 was the lowest point it dropped to. The percentage change in DNTH stock occurred in the recent session was 2.68% while the dollar amount for the price change in DNTH stock was $2.64.
-
DNTH's industry and sector of operation?
-
The NASDAQ listed DNTH is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of DNTH?
-
Adam Veness | Senior Vice President, General Counsel & Secretary
Edward G. Carr | Senior VP & Chief Accounting Officer
Judson Taylor | Senior Vice President & Head of Technical Operations
Ryan Savitz | Executive VP, CFO, Chief Business Officer & Treasurer
Jennifer Davis Ruff | Vice President and Head of Investor Relations & Corporate Affairs. -
How many employees does DNTH have?
-
Number of DNTH employees currently stands at 92. DNTH operates from 7 Times Square, New York, NY 10036, US.
-
Link for DNTH official website?
-
Official Website of DNTH is: https://dianthustx.com
-
How do I contact DNTH?
-
DNTH could be contacted at phone #929-999-4055 and can also be accessed through its website. DNTH operates from 7 Times Square, New York, NY 10036, US.
-
How many shares of DNTH are traded daily?
-
The average number of DNTH shares traded daily for last 3 months was 937.49K.
-
What is the market cap of DNTH currently?
-
The market value of DNTH currently stands at $4.23B with its latest stock price at $101.28